



May 27, 2011

Statement re Termination of QE3 Study

The NINDS has stopped the QE3 Phase III study of Coenzyme Q10 for treatment of early Parkinson's disease acting on the recommendation of the study's Data Safety Monitoring Board (DSMB). At the time of the most recent DSMB review, the results of a preplanned interim analysis showed that it would be futile to complete the study because it would be very unlikely to demonstrate a statistically significant benefit of active treatment over placebo. To date, the investigators have not found any safety concerns related to Coenzyme Q10 at dosages of 1200mg/day and 2400mg/day for up to 16 months of treatment. Site investigators and coordinators have informed participants of the study closure and have encouraged each participant to schedule a final study visit.

The QE3 study, administered by the Parkinson Study Group, enrolled 600 patients with early Parkinson's disease from 67 sites throughout North America. Participants were randomized to receive either 1200mg/d or 2400mg/d of active CoQ10 or matching placebo. All participants also received vitamin E at a dosage of 1200 IU/day.

The Principal Investigators and the Parkinson Study Group are committed to conducting a detailed analysis of the complete data set from the QE3 study and to disseminating the results through the scientific review process. All are indebted to the participants for their time and dedication to this study.

Importantly, findings of the QE3 study are specific to Parkinson's disease, and they do not reflect the possible value Coenzyme Q10 may have in other disorders.